Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome

NCT02858453 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

433

Enrollment

INDUSTRY

Sponsor class

Conditions

Interstitial Cystitis
Bladder Pain Syndrome
Painful Bladder Syndrome
Chronic Interstitial Cystitis

Interventions

DRUG: AQX-1125 100 mg
DRUG: AQX-1125 200 mg
DRUG: Placebo

Sponsor

Aquinox Pharmaceuticals (Canada) Inc.